Novartis AG (0QLR) Price & Analysis

Compare

12 Followers

0QLR Stock Chart & Stats

CHF114.23

CHF0.25(0.27%)

At close: Jan 08 4:00 PM EST

CHF114.23

CHF0.25(0.27%)

Day’s Range― - ―

52-Week RangeCHF81.22 - CHF117.12

Previous CloseN/A

Volume210.36K

Average Volume (3M)1.02M

Market Cap

CHF221.76B

Enterprise ValueCHF309.06B

Total Cash (Recent Filing)CHF9.75B

Total Debt (Recent Filing)CHF32.02B

Price to Earnings (P/E)18.7

Beta0.89

Next Earnings

Feb 04, 2026

EPS Estimate

1.53

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.73

Shares Outstanding2,112,421,900

10 Day Avg. Volume801,914

30 Day Avg. Volume1,022,628

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)4.47

Price to Sales (P/S)3.81

P/FCF Ratio14.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF115.82

Price Target Upside1.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering12

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Late-stage Pipeline And Acquisition CatalystsLate-stage trial readouts and assets from the Avidity acquisition create a pipeline-driven catalyst path with potential to deliver substantial new product launches and revenue uplift.

Successful Recent Product LaunchesRecent launches such as Pluvicto, Scemblix and Leqvio have demonstrated strong uptake and are expected to contribute meaningfully to sales momentum.

Upgraded Sales And Margin ObjectivesUpgraded sales growth guidance and a mid-term margin target above 40% indicate management expects to sustain profitability while growing revenue.

Bears Say

Acquisition-related Dilution And Earnings PressureDilution from the Avidity acquisition is expected to weigh on earnings and could pressure margins despite planned efficiency measures.

Patent Expiration RiskPatent expirations on key products remain a significant overhang that could reduce sales if new product launches do not scale as anticipated.

Valuation Premium Relative To PeersThe stock trades at a premium to peers, which could constrain upside unless the company delivers stronger-than-expected sales and earnings momentum.

Novartis AG News

Novartis initiated with a Buy at Citi

Citi analyst Graham Parry initiated coverage of Novartis (NVS) with a Buy rating and CHF 133 price target...

3d ago

NVS

AI Daily: Nvidia invests $2B in CoreWeave

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies...

4d ago

LLY

NVS

Drugmakers use AI to help progress through trials, submissions, Reuters says

AI has begun helping drug companies progress through trials and regulatory submissions, Maggie Fick and Michael Erman of...

4d ago

GSK

LLY

Amgen downgraded to Market Perform from Outperform at Bernstein

Bernstein downgraded Amgen (AMGN) to Market Perform from Outperform with an unchanged price target of $335 to reflect...

10d ago

MRK

NVS

Trump Trade: Trump announces tariffs on NATO countries over Greenland

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

10d ago

CVX

JPM

Novartis believes U.S. investment deal will shield it from tariffs, CNBC says

Novartis (NVS) CEO Vas Narasimhan “thinks” the company has an agreement with the U.S. to protect it from...

10d ago

NVS

Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here’s How to Buy Without the Risk

Johnson & Johnson ($JNJ) is set to report its Q4 earnings on January 21. Analysts expect revenue of about $24.16...

11d ago

BMY

IHE

Novartis price target raised to CHF 125 from CHF 120 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Novartis (NVS) to CHF 125 from CHF 120 and keeps...

14d ago

NVS

Novartis receives FDA Breakthrough Therapy designation for ianalumab

Novartis (NVS) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ianalumab for...

14d ago

NVS

Trump Trade: White House releases details on ‘Great Healthcare Plan’

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

14d ago

AZN

Drugmakers concerned about legal risk with FDA review program, Reuters reports

More than half a dozen major drugmakers are participating in the Trump administration’s expedited FDA review program, but...

14d ago

AZN

BMY

Novartis AG: Visible Earnings, Supportive Guidance and Attractive Risk‑Reward Underpin Buy Rating

Analyst Thibault Boutherin from Morgan Stanley maintained a Buy rating on Novartis AG and keeping the price target...

2d ago

NVS

Novartis: Buy Rating Backed by Strong Rx Momentum, De-Risked Late-Stage Pipeline and Attractive Valuation

Novartis AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from...

14d ago

NVS

Novartis AG: Strong Growth Potential and Strategic Innovations Justify Buy Rating

Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on NOVN stock, giving a Buy...

2M ago

NVS

0QLR FAQ

What was Novartis AG’s price range in the past 12 months?

Novartis AG lowest stock price was CHF81.22 and its highest was CHF117.12 in the past 12 months.

What is Novartis AG’s market cap?

Novartis AG’s market cap is CHF221.76B.

When is Novartis AG’s upcoming earnings report date?

Novartis AG’s upcoming earnings report date is Feb 04, 2026 which is in 5 days.

How were Novartis AG’s earnings last quarter?

Novartis AG released its earnings results on Oct 28, 2025. The company reported CHF1.729 earnings per share for the quarter, missing the consensus estimate of CHF1.747 by -CHF0.018.

Is Novartis AG overvalued?

According to Wall Street analysts Novartis AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novartis AG pay dividends?

Novartis AG does not currently pay dividends.

What is Novartis AG’s EPS estimate?

Novartis AG’s EPS estimate is 1.53.

How many shares outstanding does Novartis AG have?

Novartis AG has 2,112,421,900 shares outstanding.

What happened to Novartis AG’s price movement after its last earnings report?

Novartis AG reported an EPS of CHF1.729 in its last earnings report, missing expectations of CHF1.747. Following the earnings report the stock price went down -3.255%.

Which hedge fund is a major shareholder of Novartis AG?

Currently, no hedge funds are holding shares in GB:0QLR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG (0QLR) Earnings & Revenues

Historic Earnings Reports

0QLR Stock 12 Month Forecast

Average Price Target

CHF115.82

▲(1.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","109":"CHF109","134":"CHF134","96.5":"CHF96.5","121.5":"CHF121.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":133,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF133.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115.81818181818183,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF115.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF92.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,96.5,109,121.5,134],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.578,111.37969230769231,113.18138461538462,114.98307692307692,116.78476923076923,118.58646153846153,120.38815384615384,122.18984615384616,123.99153846153847,125.79323076923077,127.59492307692308,129.3966153846154,131.1983076923077,{"y":133,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.578,110.05801398601399,110.53802797202798,111.01804195804196,111.49805594405595,111.97806993006994,112.45808391608392,112.93809790209791,113.4181118881119,113.89812587412588,114.37813986013987,114.85815384615385,115.33816783216784,{"y":115.81818181818183,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.578,108.22584615384616,106.87369230769231,105.52153846153847,104.16938461538462,102.81723076923078,101.46507692307692,100.11292307692308,98.76076923076923,97.40861538461539,96.05646153846153,94.7043076923077,93.35215384615384,{"y":92,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":85.508,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.266,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.147,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.695,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.747,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.815,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.469,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.334,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.428,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.578,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >